SCHEMBL5756232

SCHEMBL5756232

Cc1ccc(C(=O)NCC2COc3ccccc3O2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.54
HPGD P15428 4/20 0.52
LMNA P02545 4/20 0.52
HTT P42858 3/20 0.52
POLB P06746 2/20 0.52
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
RECQL P46063 1/20 0.52
KMT2A Q03164 1/20 0.52
ALDH1A1 P00352 3/20 0.50
MAPK1 P28482 3/20 0.50
KDM4E B2RXH2 2/20 0.50
USP2 O75604 1/20 0.50
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
HSD17B10 Q99714 2/20 0.47
MTNR1A P48039 1/20 0.47
TSHR P16473 3/20 0.45
GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440292 0.85 HPGD (0.51) HPGDLMNAHTTPOLBMEN1
SCHEMBL4025171 0.85 LMNA (0.48) HPGDLMNAHTTPOLBMEN1
SCHEMBL5757324 0.82 ELANE (0.55) ELANEPOLBKMT2A
SCHEMBL5759586 0.81 ELANE (0.63) ELANEKMT2AALDH1A1KDM4ESMN1; SMN2
SCHEMBL5758307 0.81 KMT2A (0.58) ELANEHPGDLMNAPOLBMAPT
SCHEMBL5755732 0.81 KMT2A (0.58) ELANEHPGDLMNAPOLBMAPT
SCHEMBL5760188 0.80 ELANE (0.55) ELANEHPGDLMNAHTTPOLB
SCHEMBL5759188 0.79 ELANE (0.60) ELANEALDH1A1NPC1RAB9A
SCHEMBL5758001 0.77 ELANE (0.68) ELANEHPGDLMNAHTTMEN1
SCHEMBL5758008 0.77 ELANE (0.68) ELANEHPGDLMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1325003-B1 7-CHLORO-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINO 4,5-B|QUINOLINE-1,10-DIONE AND THE USE THEREOF FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2006-08-02 EP disclosed
EP-1325002-B1 1,2,5,10-TETRAHYDROPYRIDAZINO¬4,5-B|QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2006-05-24 EP disclosed
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
EP-1244660-B1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2006-03-22 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
EP-1577311-A1 Salts of a pyridazino aquinoline derivative and use for the treatment of pain AstraZeneca AB (SE) 2005-09-21 EP disclosed
US-6946463-B2 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain ASTRAZENECA AB (SE) 2005-09-20 US disclosed
US-6943165-B2 Compound and method for the treatment of pain ASTRAZENECA AB (SE) 2005-09-13 US disclosed
US-6933297-B2 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain ASTRAZENECA AB (CH) 2005-08-23 US disclosed
US-20050124622-A1 Compounds and methods for the treatment of pain BROWN DEAN G (US) 2005-06-09 US disclosed
US-6214826-B1 NERVOUS SYSTEM DISORDERS ZENECA LIMITED (GB) 2001-04-10 US disclosed
EP-0724583-B1 PYRIDAZINO QUINOLINE COMPOUNDS ASTRAZENECA AB (SE) 2000-12-13 EP disclosed
EP-1004582-A2 Pyridazino quinoline compounds AstraZeneca UK Limited (GB) 2000-05-31 EP disclosed
US-5837705-A AN ANTAGONIST OF EXCITATORY AMINO ACID AND GLYCINE RECEPTOR FOR TREATING NEURODEGENERATIVE DISORDER, STROKE, HYPOGLYCEMIA, ISCHEMIC ATTACK, ANOXIA OR EPILEPSY ZENECA LIMITED (GB) 1998-11-17 US disclosed
US-5744471-A NERVOUS SYSTEM DISORDERS ZENECA LIMITED (GB) 1998-04-28 US disclosed
EP-0790996-A1 PYRIDAZINOQUINOLINE COMPOUNDS ZENECA LIMITED (GB) 1997-08-27 EP disclosed
EP-0736531-A1 Alpha-substituted pyridazino quinoline compounds ZENECA LIMITED (GB) 1996-10-09 EP disclosed
EP-0724583-A1 PYRIDAZINO QUINOLINE COMPOUNDS ZENECA LIMITED (GB) 1996-08-07 EP disclosed
WO-1996015127-A1 PYRIDAZINOQUINOLINE COMPOUNDS ZENECA LIMITED (GB) 1996-05-23 WO disclosed
WO-1995011244-A1 PYRIDAZINO QUINOLINE COMPOUNDS ZENECA LIMITED (GB) 1995-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885HPGD 170/4885LMNA 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.